Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 21 2024 - 4:01PM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that
it will host a conference call and live webcast on Wednesday,
February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth
quarter and full-year 2023 financial results and recent portfolio
execution.
A live webcast will be accessible through the Investors &
Media section of the company’s website at www.kiniksa.com.
Individuals interested in participating in the call via telephone
may register here. Upon registration, all telephone participants
will receive a confirmation email detailing how to join the
conference call, including the dial-in number along with a unique
passcode and registrant ID that can be used to access the call. A
replay of the event will also be available on Kiniksa’s website
within approximately 48 hours after the event.
About KiniksaKiniksa is a commercial-stage
biopharmaceutical company focused on discovering, acquiring,
developing, and commercializing therapeutic medicines for patients
suffering from debilitating diseases with significant unmet medical
need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart,
and mavrilimumab, are based on strong biologic rationale or
validated mechanisms, target a spectrum of underserved
cardiovascular and autoimmune conditions, and offer the potential
for differentiation. For more information, please
visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor and Media ContactRachel
Frank(339) 970-9437rfrank@kiniksa.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Oct 2023 to Oct 2024